Cover Page
Cover Page - shares | 3 Months Ended | |
Mar. 31, 2022 | Apr. 27, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2022 | |
Document Transition Report | false | |
Entity File Number | 001-39592 | |
Entity Registrant Name | Kronos Bio, Inc. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 82-1895605 | |
Entity Address, Address Line One | 1300 So. El Camino Real | |
Entity Address, Address Line Two | Suite 400 | |
Entity Address, City or Town | San Mateo | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94402 | |
City Area Code | 650 | |
Local Phone Number | 781-5200 | |
Title of 12(b) Security | Common stock, $0.001 par value per share | |
Trading Symbol | KRON | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 56,732,201 | |
Entity Central Index Key | 0001741830 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Balance Sheets (Unaud
Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | |
Current assets: | |||
Cash and cash equivalents | $ 148,979 | $ 198,270 | [1] |
Short-term investments | 154,157 | 141,239 | [1] |
Prepaid expenses and other current assets | 7,455 | 8,045 | [1] |
Total current assets | 310,591 | 347,554 | [1] |
Long-term investments | 12,246 | 0 | [1] |
Property and equipment, net | 14,510 | 14,880 | [1] |
Operating lease right-of-use assets | 26,370 | 26,904 | [1] |
Restricted cash | 2,026 | 2,026 | [1] |
Other noncurrent assets | 113 | 112 | [1] |
Total assets | 365,856 | 391,476 | [1] |
Current liabilities: | |||
Accounts payable | 4,719 | 998 | [1] |
Accrued expenses | 8,328 | 9,063 | [1] |
Current portion of operating lease liabilities | 2,502 | 2,109 | [1] |
Current portion of other liabilities | 1,529 | 1,456 | [1] |
Total current liabilities | 17,078 | 13,626 | [1] |
Noncurrent operating lease liabilities | 30,963 | 31,653 | [1] |
Other noncurrent liabilities | 795 | 1,100 | [1] |
Total liabilities | 48,836 | 46,379 | [1] |
Commitments and contingencies (Note 11) | [1] | ||
Stockholders’ equity: | |||
Common stock, $0.001 par value, 200,000,000 authorized as of March 31, 2022 and December 31, 2021; 56,064,509 and 55,703,327 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively. | 56 | 56 | [1] |
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued and outstanding. | |||
Additional paid-in capital | 616,381 | 608,064 | [1] |
Accumulated deficit | (299,247) | (262,984) | [1] |
Accumulated other comprehensive income (loss) | (170) | (39) | [1] |
Total stockholders' equity | 317,020 | 345,097 | [1] |
Total liabilities and stockholders’ equity | $ 365,856 | $ 391,476 | [1] |
[1] | The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date. |
Condensed Balance Sheets (Una_2
Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 56,064,509 | 55,703,327 |
Common stock, shares outstanding (in shares) | 56,064,509 | 55,703,327 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Condensed Statements of Operati
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Operating expenses: | ||
Research and development | $ 24,438 | $ 17,594 |
General and administrative | 11,927 | 8,584 |
Total operating expenses | 36,365 | 26,178 |
Loss from operations | (36,365) | (26,178) |
Other income (expense), net: | ||
Interest and other income, net | 102 | 92 |
Total other income (expense), net | 102 | 92 |
Net loss | (36,263) | (26,086) |
Other comprehensive income (loss): | ||
Net unrealized gain (loss) on available-for-sale securities | (131) | (4) |
Net comprehensive loss | $ (36,394) | $ (26,090) |
Net loss per share, basic (in dollars per share) | $ (0.65) | $ (0.48) |
Net loss per share, diluted (in dollars per share) | $ (0.65) | $ (0.48) |
Weighted-average shares of common stock, basic (in shares) | 55,839,336 | 54,152,656 |
Weighted-average shares of common stock, diluted (in shares) | 55,839,336 | 54,152,656 |
Condensed Statements of Stockho
Condensed Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($) $ in Thousands | Total | Common Stock | Additional Paid-in Capital | Accumulated Other Comprehensive Income (Loss) | Accumulated Deficit | |
Common stock, beginning balance (in shares) at Dec. 31, 2020 | 54,073,901 | |||||
Beginning balance at Dec. 31, 2020 | $ 465,519 | $ 54 | $ 577,390 | $ (19) | $ (111,906) | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Issuance of common stock upon vesting and exercise of options and vesting of restricted stock (in shares) | 312,062 | |||||
Issuance of common stock upon vesting and exercise of options and vesting of restricted stock | 590 | 590 | ||||
Stock-based compensation expense | 5,238 | 5,238 | ||||
Net unrealized gain (loss) on available-for-sale securities | (4) | (4) | ||||
Net loss | (26,086) | (26,086) | ||||
Common stock, ending balance (in shares) at Mar. 31, 2021 | 54,385,963 | |||||
Beginning balance at Mar. 31, 2021 | 445,257 | $ 54 | 583,218 | (23) | (137,992) | |
Common stock, beginning balance (in shares) at Dec. 31, 2021 | 55,703,327 | |||||
Beginning balance at Dec. 31, 2021 | 345,097 | [1] | $ 56 | 608,064 | (39) | (262,984) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||
Issuance of common stock upon vesting and exercise of options and vesting of restricted stock (in shares) | 361,182 | |||||
Issuance of common stock upon vesting and exercise of options and vesting of restricted stock | 529 | 529 | ||||
Stock-based compensation expense | 7,788 | 7,788 | ||||
Net unrealized gain (loss) on available-for-sale securities | (131) | (131) | ||||
Net loss | (36,263) | (36,263) | ||||
Common stock, ending balance (in shares) at Mar. 31, 2022 | 56,064,509 | |||||
Beginning balance at Mar. 31, 2022 | $ 317,020 | $ 56 | $ 616,381 | $ (170) | $ (299,247) | |
[1] | The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date. |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 58 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | Dec. 31, 2021 | ||
Cash flows from operating activities: | |||||
Net loss | $ (36,263) | $ (26,086) | $ (299,200) | ||
Adjustments to reconcile net loss to cash used in operating activities: | |||||
Depreciation and amortization | 557 | 444 | |||
Net amortization/accretion on available-for-sale securities | 517 | 943 | |||
Change in accrued interest on available-for-sale securities | 343 | 16 | |||
Stock-based compensation expense | 7,788 | 5,238 | |||
Noncash lease expense | 534 | 461 | |||
Changes in operating assets and liabilities: | |||||
Prepaid expenses and other current assets | 406 | 971 | |||
Other long-term assets | (1) | 52 | |||
Accounts payable | 3,670 | (1,199) | |||
Accrued expenses | (505) | 228 | |||
Right-of-use operating assets and liabilities, net | (297) | 175 | |||
Other liabilities | (233) | (241) | |||
Net cash provided by (used in) operating activities | (23,484) | (18,998) | |||
Cash flows from investing activities: | |||||
Purchase of property and equipment | (366) | (1,505) | |||
Purchase of available-for-sale securities | (94,544) | (126,060) | |||
Maturities of marketable securities | 68,574 | 39,416 | |||
Net cash provided by (used in) investing activities | (26,336) | (88,149) | |||
Cash flows from financing activities: | |||||
Principal payments on finance lease | 0 | (5) | |||
Proceeds from issuance of common stock upon exercise of stock options | 529 | 590 | |||
Net cash provided by (used in) financing activities | 529 | 585 | |||
Net increase (decrease) in cash and cash equivalents | (49,291) | (106,562) | |||
Cash, cash equivalents and restricted cash at beginning of period | 200,296 | 250,036 | |||
Cash, cash equivalents and restricted cash at end of period | 151,005 | 143,474 | 151,005 | ||
Supplemental disclosures of non-cash activities: | |||||
Property and equipment additions included in accounts payable and accrued expenses | 47 | 588 | |||
Reduction of right-of-use asset due to modification | 0 | (1,741) | |||
Cash and cash equivalents at end of period | 148,979 | 141,448 | 148,979 | $ 198,270 | [1] |
Restricted cash at end of period | 2,026 | 2,026 | 2,026 | 2,026 | [1] |
Cash, cash equivalents and restricted cash at end of period | $ 151,005 | $ 143,474 | $ 151,005 | $ 200,296 | |
[1] | The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date. |
Nature of Operations and Basis
Nature of Operations and Basis of Presentation | 3 Months Ended |
Mar. 31, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Operations and Basis of Presentation | NATURE OF OPERATIONS AND BASIS OF PRESENTATION Kronos Bio, Inc. (Kronos or the Company), a Delaware corporation, was incorporated on June 2, 2017. The Company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. The Company operates in one business segment: the development of biopharmaceutical products. Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Need for Additional Capital The Company has incurred net operating losses since its inception of $299.2 million as of March 31, 2022. The Company expects that its cash, cash equivalents and investments as of March 31, 2022 will enable it to fund its planned operating expenses and capital expenditure requirements for at least one year from the date of issuance of these condensed financial statements. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying financial statements are filed with the SEC. The Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s results may be adversely affected. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The future viability of the Company is dependent on its ability to generate cash from operating activities or to raise additional capital to finance its operations. The Company’s failure to raise capital as and when needed could have a material adverse effect on its financial condition and ability to pursue business strategies. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaboration arrangements or obtain government grants. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce, or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. In the event that the Company |
Significant Accounting Policies
Significant Accounting Policies, Estimates and Judgments | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Significant Accounting Policies, Estimates and Judgments | SIGNIFICANT ACCOUNTING POLICIES, ESTIMATES AND JUDGMENTS Unaudited Interim Financial Information The accompanying balance sheet as of March 31, 2022, the statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021, the statements of stockholders’ equity (deficit) as of March 31, 2022 and 2021, the statements of cash flows for the three months ended March 31, 2022 and 2021, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The unaudited interim financial statements have been prepared on a basis consistent with the Company’s audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2022 and the results of its operations for the three months ended March 31, 2022 and 2021. The results for the three months ended March 31, 2022 are not necessarily indicative of results to be expected for the full year ending December 31, 2022, any other interim periods, or any future year or period. These financial statements should be read in conjunction with the Company's audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 24, 2022 (Annual Report). Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates. Significant Accounting Policies There have been no significant changes to the accounting policies during the three months ended March 31, 2022, as compared to the significant accounting policies described in Note 2 of the “Notes to Financial Statements” of the Company’s audited financial statements included in its Annual Report. Recently Issued and Adopted Accounting Pronouncements In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force) |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | FAIR VALUE MEASUREMENTSThe Company follows authoritative accounting guidance, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The Company measures and reports its cash equivalents and investments at fair value. Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level 1. Investments measured at fair value based on inputs other than quoted prices that are derived from observable market data are classified as Level 2. Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March 31, 2022 and December 31, 2021 were as follows: March 31, 2022 Level 1 Level 2 Level 3 Fair Value (in thousands) Financial Assets: Money market funds $ 118,610 $ — $ — $ 118,610 Corporate bonds — 50,864 — 50,864 U.S. agency securities — 4,978 — 4,978 U.S. treasury securities 130,630 — — 130,630 Total financial assets $ 249,240 $ 55,842 $ — $ 305,082 December 31, 2021 Level 1 Level 2 Level 3 Fair Value (in thousands) Financial Assets: Money market funds $ 188,923 $ — $ — $ 188,923 Corporate bonds — 63,620 — 63,620 U.S. treasury securities 79,394 — — 79,394 Total financial assets $ 268,317 $ 63,620 $ — $ 331,937 The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities. The Company’s Level 2 securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly. The Company did not have any financial assets or liabilities as of March 31, 2022 and December 31, 2021 that required Level 3 inputs. |
Investments
Investments | 3 Months Ended |
Mar. 31, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Investments | INVESTMENTS The fair value and amortized cost of available-for-sale securities by major security type as of March 31, 2022 and December 31, 2021 were as follows: March 31, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value (in thousands) Money market funds $ 118,610 $ — $ — $ 118,610 Corporate bonds 50,932 1 (69) 50,864 U.S. agency securities 4,981 — (3) 4,978 U.S. treasury securities 130,729 1 (100) 130,630 Total cash equivalents and investments $ 305,252 $ 2 $ (172) $ 305,082 December 31, 2021 Amortized Cost Unrealized Gains Unrealized Losses Fair Value (in thousands) Money market funds $ 188,923 $ — $ — $ 188,923 Corporate bonds 63,647 2 (29) 63,620 U.S. treasury securities 79,406 — (12) 79,394 Total cash equivalents and investments $ 331,976 $ 2 $ (41) $ 331,937 These available-for-sale securities were classified on the Company’s balance sheets as of March 31, 2022 and December 31, 2021 as: Fair Value March 31, 2022 December 31, 2021 (in thousands) Cash equivalents $ 138,679 $ 190,698 Short-term investments 154,157 141,239 Long-term investments 12,246 — Total cash equivalents and investments $ 305,082 $ 331,937 The fair values of available-for-sale securities by contractual maturity as of March 31, 2022 and December 31, 2021 were as follows: March 31, 2022 December 31, 2021 (in thousands) Due in 1 year or less $ 292,836 $ 143,014 Due in 1 to 2 years 12,246 — Instruments not due at a single maturity date — 188,923 Total cash equivalents and investments $ 305,082 $ 331,937 As of March 31, 2022 and December 31, 2021, the remaining contractual maturities of available-for-sale securities were less than two years. There have been no significant realized losses on available-for-sale securities for any of the periods presented in the accompanying financial statements. Based on the Company’s review of its available-for-sale securities, the Company believes that it had no other-than-temporary impairments on these securities as of March 31, 2022 and December 31, 2021 because the Company does not intend to sell these securities nor does it believe that it will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were immaterial for any of the periods presented in the accompanying financial statements. As of March 31, 2022 and December 31, 2021, unrealized losses on available-for-sale investments are not attributed to credit risk. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company’s marketable securities are due to market factors. |
Prepaid Expenses And Other Curr
Prepaid Expenses And Other Current Assets | 3 Months Ended |
Mar. 31, 2022 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Prepaid Expenses and Other Current Assets | PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following as of March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 (in thousands) Accrued interest on short-term available-for-sale securities $ 661 $ 816 Prepaid equipment service contracts 446 360 Prepaid external research and development and outside services 3,086 3,074 Prepaid software 1,054 624 Prepaid insurance 1,691 2,644 Prepaid rent and other 517 527 Total prepaid expenses and other current assets $ 7,455 $ 8,045 |
Property and Equipment, Net
Property and Equipment, Net | 3 Months Ended |
Mar. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment, Net | PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following as of March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 (in thousands) Property and equipment: Lab equipment $ 8,317 $ 8,164 Leasehold improvements 9,344 9,335 Furniture and fixtures 608 596 Computer equipment 58 44 Total property and equipment 18,327 18,139 Less: Accumulated depreciation and amortization (3,817) (3,259) Total property and equipment, net $ 14,510 $ 14,880 Depreciation and amortization expense was $0.6 million and $0.4 million for the three months ended March 31, 2022 and 2021, respectively. |
Accrued Expenses and Current Po
Accrued Expenses and Current Portion of Other Liabilities | 3 Months Ended |
Mar. 31, 2022 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Current Portion of Other Liabilities | ACCRUED EXPENSES AND CURRENT PORTION OF OTHER LIABILITIES Accrued expenses consisted of the following as of March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 (in thousands) Accrued compensation $ 1,258 $ 4,570 Accrued taxes 50 — External research and development 5,751 2,655 Accrued outside services 1,227 1,598 Other accrued expenses 42 240 Total accrued expenses $ 8,328 $ 9,063 March 31, 2022 December 31, 2021 (in thousands) Current portion of unvested early exercised share liability 1,225 1,364 ESPP withholdings 304 92 Total current portion of other liabilities $ 1,529 $ 1,456 |
Stock-Based Compensation
Stock-Based Compensation | 3 Months Ended |
Mar. 31, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Stock-Based Compensation | STOCK-BASED COMPENSATION 2020 Equity Incentive Plan In October 2020, the Company adopted its 2020 Equity Incentive Plan (the 2020 Plan) which replaced the 2017 Equity Incentive Plan (Prior Plan) upon completion of the IPO. The 2020 Plan provides for the grant of incentive stock options or nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards and other forms of awards to employees, directors, and consultants of the Company. The number of shares of common stock reserved for issuance under the 2020 Plan will automatically increase each year for a period of ten years, beginning in 2021 and continuing through 2030, in an amount equal to (1) 5.0% of the total number of shares of the Company’s common stock outstanding on December 31 of the immediately preceding year, or (2) a lesser number of shares determined by the Board of Directors no later than December 31 of the immediately preceding year. As of March 31, 2022, the maximum number of shares of common stock that may be issued was 17,568,821 shares. The Company recognizes the impact of forfeitures on stock-based compensation expense as forfeitures occur. The Company applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Options shall not have an exercise price less than 100% of the fair market value of the Company’s common stock on the grant date. Vesting periods are determined at the discretion of the Board of Directors. Stock options typically vest over four years. The maximum contractual term is 10 years. As of March 31, 2022, there were 4,911,664 shares reserved by the Company under the 2020 Plan for the future issuance of equity awards. Stock Options Stock option activity under the 2020 Plan as of March 31, 2022 is summarized as follows: Number of Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value (in years) (in thousands) Balance, December 31, 2021 6,590,400 $ 14.33 Granted 1,905,502 7.41 Forfeited (131,795) 11.73 Exercised (246,029) 2.15 Balance, March 31, 2022 8,118,078 $ 13.12 8.76 $ 11,974 The aggregate intrinsic values of options outstanding was calculated as the difference between the exercise price of the options and the closing price of the Company’s common stock on the Nasdaq Global Select Market on March 31, 2022. There was no future tax benefit related to options exercised, as the Company had accumulated net operating losses as of March 31, 2022 and December 31, 2021. The weighted-average grant-date fair value per share of stock options granted, using the Black-Scholes option pricing model, was $5.05 during the three months ended March 31, 2022. As of March 31, 2022 and December 31, 2021, there was $53.5 million and $49.9 million of unrecognized stock-based compensation related to stock options, respectively, which is expected to be recognized over a weighted-average period of 2.91 and 2.93 years, respectively. 2020 Employee Stock Purchase Plan In October 2020, the Company adopted its 2020 Employee Stock Purchase Plan (ESPP), which initially reserved 688,000 shares of the Company’s common stock for employee purchase under terms and provisions established by the Board of Directors. The number of shares of our common stock reserved for issuance under the ESPP automatically increases in 2021 and continues to increase through 2030, by the lesser of (i) 1.0% of the total number of shares of common stock outstanding on December 31 of the immediately preceding year, and (ii) 1,376,000 shares, except before the date of any increase, the Board of Directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii). The Company issued and sold zero shares of common stock during the three months ended March 31, 2022 and 2021 under the ESPP. The Company has 1,718,410 shares reserved for future issuance as of March 31, 2022 . Restricted Stock Restricted stock awards and units as of March 31, 2022 are summarized as follows: Number of Restricted Stock Weighted-Average Grant Date Fair Value Weighted-Average Remaining Vesting Life Aggregate Intrinsic Value (in years) (in thousands) Unvested, December 31, 2021 787,719 $ 26.88 Granted 836,446 7.11 Vested and converted to shares (115,153) 27.22 Forfeited (45,244) 14.57 Unvested, March 31, 2022 1,463,768 $ 16.08 2.41 $ 10,583 As of March 31, 2022, there was $20.8 million of unrecognized stock-based compensation related to RSUs, which is expected to be recognized over a weighted average period of 2.06 years. As of March 31, 2022, there was $0.3 million of unrecognized stock-based compensation related to RSAs, which is expected to be recognized over a weighted average period of 2.33 years. Stock-Based Compensation Summary Total stock-based compensation expense related to stock options, restricted stock units, restricted stock awards and the employee stock purchase plan for the three months ended March 31, 2022 and 2021 as follows: Three months ended March 31, 2022 2021 (in thousands) Research and development expenses $ 3,804 $ 2,554 General and administrative expenses 3,984 2,684 Total stock-based compensation expense $ 7,788 $ 5,238 Early Exercised Options The Company allows certain of its employees and its consultants to exercise options granted under the Prior Plan prior to vesting. The shares related to early exercised stock options are subject to the Company’s lapsing repurchase right upon termination of employment or service on the Board of Directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The early exercise by an employee or consultant of a stock option is not considered to be a substantive exercise for accounting purposes, and therefore the payment received by the employer for the exercise price is recognized as a liability. For accounting purposes, unvested early exercised shares are not considered issued and outstanding and therefore not reflected as issued and outstanding in the accompanying balance sheets or the accompanying statements of stockholders' equity (deficit) until the awards vest. The deposits received are initially recorded in current portion of other liabilities and other noncurrent liabilities for the noncurrent portion. The liabilities are reclassified to common stock and paid-in capital as the repurchase right lapses. At March 31, 2022 and December 31, 2021, there was $1.2 million and $1.4 million recorded in current portion of other liabilities, and $0.8 million and $1.1 million recorded in other noncurrent liabilities, respectively, related to shares held by employees and nonemployees that were subject to repurchase. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | INCOME TAXES The Company did not record any income tax expense for the three months ended March 31, 2022 and 2021. The Company has incurred net operating losses for all the periods presented and has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has recorded a full valuation allowance against all of its deferred tax assets as it is not more likely than not that such assets will be realized in the near future. It is the Company’s policy to record penalties and interest related to income taxes as a component of income tax expense. The Company has not recorded any interest or penalties related to income taxes during the three months ended March 31, 2022 and 2021. The Company has not identified any new uncertain tax positions as of March 31, 2022. Unrecognized tax benefits are not expected to change during the next 12 months. The reversal of the unrecognized tax benefits would not affect the effective tax rate. The Company is subject to examination by U.S. federal and state tax authorities for all years since its inception. |
Net Loss Per Share
Net Loss Per Share | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | NET LOSS PER SHARE The following table summarizes the computation of basic and diluted net loss per share of the Company for the three months ended March 31, 2022 and 2021: Three months ended March 31, 2022 2021 (in thousands, except share and per share amounts) Net loss $ (36,263) $ (26,086) Weighted-average common stock outstanding, basic and diluted 55,839,336 54,152,656 Net loss per share, basic and diluted $ (0.65) $ (0.48) The Company’s potentially dilutive securities, which include options to purchase shares of the Company's common stock and restricted stock subject to future vesting, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of common stock outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each stated period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: March 31, 2022 March 31, 2021 Stock options to purchase common stock 7,539,416 5,307,444 Early exercised stock options subject to future vesting 578,662 1,443,842 Restricted stock awards subject to future vesting 80,016 217,877 Restricted stock units subject to future vesting 1,383,752 904,847 Expected shares to be purchased under Employee Stock Purchase Plan 380,500 136,013 Total 9,962,346 8,010,023 |
Commitment and Contingencies
Commitment and Contingencies | 3 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | COMMITMENTS AND CONTINGENCIES R&D Services Agreement In October 2021, the Company entered into an agreement for research and development services (Tempus Agreement) with Tempus Labs, Inc. (Tempus), pursuant to which Tempus agreed to provide the Company with research and development services for a period of three years. The three primary services are analytical services, data licensing, and organoid services. The Company intends to utilize the services contemplated under the Tempus Agreement to advance the development of KB-0742 and lanraplenib. In consideration for the access to the services throughout the term of the Tempus Agreement, the Company has agreed to pay an annual minimum commitment of $1.5 million in year one, $2.0 million in year two, and $2.5 million in year three. Payments are made in quarterly installments. In addition, the Company is required to make milestone payments upon successful achievement of certain regulatory milestones for KB-0742, lanraplenib, and other discovery pipeline compounds up to a combined maximum of $22.4 million. For each milestone payment that becomes due, the Company has the right to pay up to 50% of such milestone payment amount in shares of its common stock as long as certain regulatory requirements are met. As of March 31, 2022, there were no milestone payments due. Asset Purchase Agreement In July 2020, the Company entered into an asset purchase agreement (Gilead Asset Purchase Agreement) with Gilead Sciences, Inc. (Gilead), pursuant to which the Company acquired certain assets from Gilead related to entospletinib and lanraplenib, and patents and other intellectual property covering or related to the development, manufacture and commercialization of entospletinib and lanraplenib. Under the agreement, the Company is required to make milestone and royalty payments upon successful achievement of certain regulatory and sales milestones for the acquired assets. Upon initiation of our registrational Phase 3 clinical trial of entospletinib in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations in December 2021, we paid a milestone to Gilead of $29.0 million. We are currently unable to estimate the timing or likelihood of achieving remaining milestones or generating future product sales. Purchase Commitments In the normal course of business, the Company enters into contracts with CROs for preclinical studies and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred. Contingencies In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown, because it involves claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Indemnification In accordance with the Company’s amended and restated certificate of incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving in such capacity. There have been no claims to date, and the Company has a directors and officers liability insurance policy that may enable it to recover a portion of any amounts paid for future claims. |
Leases
Leases | 3 Months Ended |
Mar. 31, 2022 | |
Leases [Abstract] | |
Leases | LEASES In March 2020, the Company entered into an 11-year lease agreement to move its research and development operations from 21 Erie Street, Cambridge, Massachusetts, to a 40,514 square-feet facility at 301 Binney Street, Cambridge, Massachusetts (Cambridge facility). The lease commenced on February 28, 2020 with an initial annual base rent of $4.1 million. The initial rent payment was paid as of September 30, 2020, with rent payments escalating 3.0% annually after the initial 12 payments. As discussed in Note 2, the Company executed a letter of credit for $2.0 million in connection with the lease. The lease includes $3.7 million in certain tenant improvement allowances, which the Company included in its calculation of the right-of-use asset in the lease at commencement. As of March 31, 2022, $3.7 million in improvement costs incurred by the Company were reimbursed by the lessor and are now included within the total lease liability. In connection with the lease, the Company recognized an operating lease right-of-use asset of $23.2 million and $23.6 million and an aggregate lease liability of $29.3 million and $29.7 million as of March 31, 2022 and December 31, 2021, respectively. The remaining lease term is 8 years and 11 months, and the estimated incremental borrowing rate is 8.50%. In February 2021, the Company entered into a new lease agreement for its office space in San Mateo, California to move from its suites, totaling 8,075 square-feet, to a larger suite totaling 17,340 square-feet, and relocated in the third quarter of 2021. The Company accounted for this change in lease term of the original suites as a modification of the originally amended lease. As a result of the modification, the operating right-of-use asset and lease liability were remeasured as of the modification date. The new 17,340 square foot suite was treated as a separate lease for accounting purposes. The initial annual base rent for the new space was $1.2 million, and such amount increases by 3% annually on each anniversary of the new premises commencement date. In connection with the larger space leased, the Company has also made an additional one-time cash security deposit in the amount of $59,000. The new lease commenced in April 2021 and the new lease agreement extends the termination date from April 30, 2025 to August 31, 2026. In connection with the lease, the Company recognized an operating lease right-of-use asset of $3.2 million and $3.3 million and an aggregate lease liability of $4.2 million and $4.1 million as of March 31, 2022 and December 31, 2021, respectively. The remaining lease term is 4 years and 3 months, and the estimated incremental borrowing rate is 11.18%. The following table summarizes the presentation of the Company’s operating leases in its balance sheets as of March 31, 2022 and December 31, 2021: Balance Sheet Caption March 31, 2022 December 31, 2021 (in thousands) Assets: Operating lease assets $ 26,370 $ 26,904 Liabilities: Current portion of operating lease liabilities $ 2,502 $ 2,109 Noncurrent operating lease liabilities 30,963 31,653 Total operating lease liabilities $ 33,465 $ 33,762 The effect of finance lease costs in the Company’s statements of operations and comprehensive loss was immaterial for the three months ended March 31, 2022 and 2021. The following table summarizes the effect of operating lease costs in the Company’s statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021 : Statement of Operations and Comprehensive Loss Caption Three months ended March 31, 2022 2021 (in thousands) Research and development $ 767 $ 1,008 General and administrative 511 376 Total operating lease cost $ 1,278 $ 1,384 The Company made cash payments of $1.0 million and $1.2 million under the lease agreements during the three months ended March 31, 2022 and 2021, respectively. The undiscounted future non-cancellable lease payments under the Company's operating leases as of March 31, 2022 for the next five years and thereafter is expected to be as follows: Period Ending December 31, Amount (in thousands) Remaining nine months of 2022 $ 3,977 2023 5,581 2024 5,749 2025 5,921 2026 and thereafter 26,707 Total undiscounted lease payments 47,935 Less: Present value adjustment (14,470) Present value of operating lease liabilities $ 33,465 |
Leases | LEASES In March 2020, the Company entered into an 11-year lease agreement to move its research and development operations from 21 Erie Street, Cambridge, Massachusetts, to a 40,514 square-feet facility at 301 Binney Street, Cambridge, Massachusetts (Cambridge facility). The lease commenced on February 28, 2020 with an initial annual base rent of $4.1 million. The initial rent payment was paid as of September 30, 2020, with rent payments escalating 3.0% annually after the initial 12 payments. As discussed in Note 2, the Company executed a letter of credit for $2.0 million in connection with the lease. The lease includes $3.7 million in certain tenant improvement allowances, which the Company included in its calculation of the right-of-use asset in the lease at commencement. As of March 31, 2022, $3.7 million in improvement costs incurred by the Company were reimbursed by the lessor and are now included within the total lease liability. In connection with the lease, the Company recognized an operating lease right-of-use asset of $23.2 million and $23.6 million and an aggregate lease liability of $29.3 million and $29.7 million as of March 31, 2022 and December 31, 2021, respectively. The remaining lease term is 8 years and 11 months, and the estimated incremental borrowing rate is 8.50%. In February 2021, the Company entered into a new lease agreement for its office space in San Mateo, California to move from its suites, totaling 8,075 square-feet, to a larger suite totaling 17,340 square-feet, and relocated in the third quarter of 2021. The Company accounted for this change in lease term of the original suites as a modification of the originally amended lease. As a result of the modification, the operating right-of-use asset and lease liability were remeasured as of the modification date. The new 17,340 square foot suite was treated as a separate lease for accounting purposes. The initial annual base rent for the new space was $1.2 million, and such amount increases by 3% annually on each anniversary of the new premises commencement date. In connection with the larger space leased, the Company has also made an additional one-time cash security deposit in the amount of $59,000. The new lease commenced in April 2021 and the new lease agreement extends the termination date from April 30, 2025 to August 31, 2026. In connection with the lease, the Company recognized an operating lease right-of-use asset of $3.2 million and $3.3 million and an aggregate lease liability of $4.2 million and $4.1 million as of March 31, 2022 and December 31, 2021, respectively. The remaining lease term is 4 years and 3 months, and the estimated incremental borrowing rate is 11.18%. The following table summarizes the presentation of the Company’s operating leases in its balance sheets as of March 31, 2022 and December 31, 2021: Balance Sheet Caption March 31, 2022 December 31, 2021 (in thousands) Assets: Operating lease assets $ 26,370 $ 26,904 Liabilities: Current portion of operating lease liabilities $ 2,502 $ 2,109 Noncurrent operating lease liabilities 30,963 31,653 Total operating lease liabilities $ 33,465 $ 33,762 The effect of finance lease costs in the Company’s statements of operations and comprehensive loss was immaterial for the three months ended March 31, 2022 and 2021. The following table summarizes the effect of operating lease costs in the Company’s statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021 : Statement of Operations and Comprehensive Loss Caption Three months ended March 31, 2022 2021 (in thousands) Research and development $ 767 $ 1,008 General and administrative 511 376 Total operating lease cost $ 1,278 $ 1,384 The Company made cash payments of $1.0 million and $1.2 million under the lease agreements during the three months ended March 31, 2022 and 2021, respectively. The undiscounted future non-cancellable lease payments under the Company's operating leases as of March 31, 2022 for the next five years and thereafter is expected to be as follows: Period Ending December 31, Amount (in thousands) Remaining nine months of 2022 $ 3,977 2023 5,581 2024 5,749 2025 5,921 2026 and thereafter 26,707 Total undiscounted lease payments 47,935 Less: Present value adjustment (14,470) Present value of operating lease liabilities $ 33,465 |
Related Parties
Related Parties | 3 Months Ended |
Mar. 31, 2022 | |
Related Party Transactions [Abstract] | |
Related Parties | RELATED PARTIES On December 1, 2017, the Company entered into a services agreement with Two River Consulting, LLC (Two River) to provide various clinical development, operational, managerial, accounting and financial, and administrative services to the Company. Arie Belldegrun, M.D., FACS, the Chairman of the Board of Directors, is the Chairman of Two River. Mr. Joshua Kazam and Mr. David Tanen, each a director of the Company, are each partners of Two River. Mr. Christopher Wilfong, a strategic advisor to the Company, is an Operating Partner of Two River and Mr. Sean Algeo, serving as a financial consultant to the Company, is the Chief Financial Officer of Two River. During the three months ended March 31, 2022 and 2021, the Company incurred expense of $23,000 and $0.2 million, respectively, for these services. In 2019, the Company entered into a consulting agreement with Bellco Capital, LLC (Bellco) to provide various executive services to the Company. Arie Belldegrun, M.D., FACS, the Chairman of the Board of Directors, is the Chairman of Bellco. Rebecka Belldegrun, M.D., who served as a director of the Company through January 25, 2021, is the President and Chief Executive Officer of Bellco. During the three months ended March 31, 2022 and 2021, the Company incurred expense of $6,300 and $6,300, respectively, for these services. |
Significant Accounting Polici_2
Significant Accounting Policies, Estimates and Judgments (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Unaudited Interim Financial Information | Unaudited Interim Financial Information The accompanying balance sheet as of March 31, 2022, the statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021, the statements of stockholders’ equity (deficit) as of March 31, 2022 and 2021, the statements of cash flows for the three months ended March 31, 2022 and 2021, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The unaudited interim financial statements have been prepared on a basis consistent with the Company’s audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2022 and the results of its operations for the three months ended March 31, 2022 and 2021. The results for the three months ended March 31, 2022 are not necessarily indicative of results to be expected for the full year ending December 31, 2022, any other interim periods, or any future year or period. These financial statements should be read in conjunction with the Company's audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 24, 2022 (Annual Report). |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the accrual of research and development expenses, the fair value of investments, income tax uncertainties, the valuation of equity instruments and the incremental borrowing rate for determining the operating lease assets and liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates. |
Recently Issued and Adopted Accounting Pronouncements | Recently Issued and Adopted Accounting Pronouncements In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force) |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March 31, 2022 and December 31, 2021 were as follows: March 31, 2022 Level 1 Level 2 Level 3 Fair Value (in thousands) Financial Assets: Money market funds $ 118,610 $ — $ — $ 118,610 Corporate bonds — 50,864 — 50,864 U.S. agency securities — 4,978 — 4,978 U.S. treasury securities 130,630 — — 130,630 Total financial assets $ 249,240 $ 55,842 $ — $ 305,082 December 31, 2021 Level 1 Level 2 Level 3 Fair Value (in thousands) Financial Assets: Money market funds $ 188,923 $ — $ — $ 188,923 Corporate bonds — 63,620 — 63,620 U.S. treasury securities 79,394 — — 79,394 Total financial assets $ 268,317 $ 63,620 $ — $ 331,937 |
Investments (Tables)
Investments (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Investments, Debt and Equity Securities [Abstract] | |
Investments Classified by Contractual Maturity Date | The fair value and amortized cost of available-for-sale securities by major security type as of March 31, 2022 and December 31, 2021 were as follows: March 31, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value (in thousands) Money market funds $ 118,610 $ — $ — $ 118,610 Corporate bonds 50,932 1 (69) 50,864 U.S. agency securities 4,981 — (3) 4,978 U.S. treasury securities 130,729 1 (100) 130,630 Total cash equivalents and investments $ 305,252 $ 2 $ (172) $ 305,082 December 31, 2021 Amortized Cost Unrealized Gains Unrealized Losses Fair Value (in thousands) Money market funds $ 188,923 $ — $ — $ 188,923 Corporate bonds 63,647 2 (29) 63,620 U.S. treasury securities 79,406 — (12) 79,394 Total cash equivalents and investments $ 331,976 $ 2 $ (41) $ 331,937 These available-for-sale securities were classified on the Company’s balance sheets as of March 31, 2022 and December 31, 2021 as: Fair Value March 31, 2022 December 31, 2021 (in thousands) Cash equivalents $ 138,679 $ 190,698 Short-term investments 154,157 141,239 Long-term investments 12,246 — Total cash equivalents and investments $ 305,082 $ 331,937 The fair values of available-for-sale securities by contractual maturity as of March 31, 2022 and December 31, 2021 were as follows: March 31, 2022 December 31, 2021 (in thousands) Due in 1 year or less $ 292,836 $ 143,014 Due in 1 to 2 years 12,246 — Instruments not due at a single maturity date — 188,923 Total cash equivalents and investments $ 305,082 $ 331,937 |
Prepaid Expenses And Other Cu_2
Prepaid Expenses And Other Current Assets (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Schedule of Prepaid Expenses and Other Assets | Prepaid expenses and other current assets consisted of the following as of March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 (in thousands) Accrued interest on short-term available-for-sale securities $ 661 $ 816 Prepaid equipment service contracts 446 360 Prepaid external research and development and outside services 3,086 3,074 Prepaid software 1,054 624 Prepaid insurance 1,691 2,644 Prepaid rent and other 517 527 Total prepaid expenses and other current assets $ 7,455 $ 8,045 |
Property and Equipment, Net (Ta
Property and Equipment, Net (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment | Property and equipment, net consisted of the following as of March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 (in thousands) Property and equipment: Lab equipment $ 8,317 $ 8,164 Leasehold improvements 9,344 9,335 Furniture and fixtures 608 596 Computer equipment 58 44 Total property and equipment 18,327 18,139 Less: Accumulated depreciation and amortization (3,817) (3,259) Total property and equipment, net $ 14,510 $ 14,880 |
Accrued Expenses And Current _2
Accrued Expenses And Current Portion Of Other Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Liabilities | Accrued expenses consisted of the following as of March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 (in thousands) Accrued compensation $ 1,258 $ 4,570 Accrued taxes 50 — External research and development 5,751 2,655 Accrued outside services 1,227 1,598 Other accrued expenses 42 240 Total accrued expenses $ 8,328 $ 9,063 |
Other Current Liabilities | Current portion of other liabilities consist of the following as of March 31, 2022 and December 31, 2021: March 31, 2022 December 31, 2021 (in thousands) Current portion of unvested early exercised share liability 1,225 1,364 ESPP withholdings 304 92 Total current portion of other liabilities $ 1,529 $ 1,456 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Stock Option Activity | Stock option activity under the 2020 Plan as of March 31, 2022 is summarized as follows: Number of Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value (in years) (in thousands) Balance, December 31, 2021 6,590,400 $ 14.33 Granted 1,905,502 7.41 Forfeited (131,795) 11.73 Exercised (246,029) 2.15 Balance, March 31, 2022 8,118,078 $ 13.12 8.76 $ 11,974 |
Schedule of Nonvested Share Activity | Restricted stock awards and units as of March 31, 2022 are summarized as follows: Number of Restricted Stock Weighted-Average Grant Date Fair Value Weighted-Average Remaining Vesting Life Aggregate Intrinsic Value (in years) (in thousands) Unvested, December 31, 2021 787,719 $ 26.88 Granted 836,446 7.11 Vested and converted to shares (115,153) 27.22 Forfeited (45,244) 14.57 Unvested, March 31, 2022 1,463,768 $ 16.08 2.41 $ 10,583 |
Stock-based Compensation, Classified in Statements of Operations | Total stock-based compensation expense related to stock options, restricted stock units, restricted stock awards and the employee stock purchase plan for the three months ended March 31, 2022 and 2021 as follows: Three months ended March 31, 2022 2021 (in thousands) Research and development expenses $ 3,804 $ 2,554 General and administrative expenses 3,984 2,684 Total stock-based compensation expense $ 7,788 $ 5,238 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted | The following table summarizes the computation of basic and diluted net loss per share of the Company for the three months ended March 31, 2022 and 2021: Three months ended March 31, 2022 2021 (in thousands, except share and per share amounts) Net loss $ (36,263) $ (26,086) Weighted-average common stock outstanding, basic and diluted 55,839,336 54,152,656 Net loss per share, basic and diluted $ (0.65) $ (0.48) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The Company excluded the following potential shares of common stock, presented based on amounts outstanding at each stated period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect: March 31, 2022 March 31, 2021 Stock options to purchase common stock 7,539,416 5,307,444 Early exercised stock options subject to future vesting 578,662 1,443,842 Restricted stock awards subject to future vesting 80,016 217,877 Restricted stock units subject to future vesting 1,383,752 904,847 Expected shares to be purchased under Employee Stock Purchase Plan 380,500 136,013 Total 9,962,346 8,010,023 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Leases [Abstract] | |
Assets and Liabilities, Operating Leases, Lessee | The following table summarizes the presentation of the Company’s operating leases in its balance sheets as of March 31, 2022 and December 31, 2021: Balance Sheet Caption March 31, 2022 December 31, 2021 (in thousands) Assets: Operating lease assets $ 26,370 $ 26,904 Liabilities: Current portion of operating lease liabilities $ 2,502 $ 2,109 Noncurrent operating lease liabilities 30,963 31,653 Total operating lease liabilities $ 33,465 $ 33,762 |
Summary of Lease Costs | The following table summarizes the effect of operating lease costs in the Company’s statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021 : Statement of Operations and Comprehensive Loss Caption Three months ended March 31, 2022 2021 (in thousands) Research and development $ 767 $ 1,008 General and administrative 511 376 Total operating lease cost $ 1,278 $ 1,384 |
Schedule of Maturities on Lease Liabilities | The undiscounted future non-cancellable lease payments under the Company's operating leases as of March 31, 2022 for the next five years and thereafter is expected to be as follows: Period Ending December 31, Amount (in thousands) Remaining nine months of 2022 $ 3,977 2023 5,581 2024 5,749 2025 5,921 2026 and thereafter 26,707 Total undiscounted lease payments 47,935 Less: Present value adjustment (14,470) Present value of operating lease liabilities $ 33,465 |
Nature of Operations and Basi_2
Nature of Operations and Basis of Presentation (Details) $ in Thousands | 3 Months Ended | 58 Months Ended | |
Mar. 31, 2022USD ($)segment | Mar. 31, 2021USD ($) | Mar. 31, 2022USD ($) | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Number of operating segments | segment | 1 | ||
Net loss | $ | $ 36,263 | $ 26,086 | $ 299,200 |
Fair Value Measurements (Detail
Fair Value Measurements (Details) - Fair Value, Recurring - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total financial assets | $ 305,082 | $ 331,937 |
Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Money market funds | 118,610 | 188,923 |
Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 50,864 | 63,620 |
U.S. agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 4,978 | |
U.S. treasury securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 130,630 | 79,394 |
Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total financial assets | 249,240 | 268,317 |
Level 1 | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Money market funds | 118,610 | 188,923 |
Level 1 | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 0 | 0 |
Level 1 | U.S. agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 0 | |
Level 1 | U.S. treasury securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 130,630 | 79,394 |
Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total financial assets | 55,842 | 63,620 |
Level 2 | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Money market funds | 0 | 0 |
Level 2 | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 50,864 | 63,620 |
Level 2 | U.S. agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 4,978 | |
Level 2 | U.S. treasury securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 0 | 0 |
Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Total financial assets | 0 | 0 |
Level 3 | Money market funds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Money market funds | 0 | 0 |
Level 3 | Corporate bonds | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 0 | 0 |
Level 3 | U.S. agency securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | 0 | |
Level 3 | U.S. treasury securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, fair value | $ 0 | $ 0 |
Investments - Fair Value and Am
Investments - Fair Value and Amortized Cost (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Schedule of Held-to-maturity Securities [Line Items] | ||
Money market funds, amortized cost | $ 138,679 | $ 190,698 |
Total cash equivalents and investments, amortized cost | 305,252 | 331,976 |
Total cash equivalents and investments, unrealized gains | 2 | 2 |
Total cash equivalents and investments, unrealized losses | (172) | (41) |
Total cash equivalents and investments, fair value | 305,082 | 331,937 |
Money market funds | ||
Schedule of Held-to-maturity Securities [Line Items] | ||
Money market funds, amortized cost | 118,610 | 188,923 |
Corporate bonds | ||
Schedule of Held-to-maturity Securities [Line Items] | ||
Amortized Cost | 50,932 | 63,647 |
Unrealized Gains | 1 | 2 |
Unrealized Losses | (69) | (29) |
Fair Value | 50,864 | 63,620 |
U.S. agency securities | ||
Schedule of Held-to-maturity Securities [Line Items] | ||
Amortized Cost | 4,981 | |
Unrealized Gains | 0 | |
Unrealized Losses | (3) | |
Fair Value | 4,978 | |
U.S. treasury securities | ||
Schedule of Held-to-maturity Securities [Line Items] | ||
Amortized Cost | 130,729 | 79,406 |
Unrealized Gains | 1 | 0 |
Unrealized Losses | (100) | (12) |
Fair Value | $ 130,630 | $ 79,394 |
Investments - Balance Sheet (De
Investments - Balance Sheet (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | |
Investments, Debt and Equity Securities [Abstract] | |||
Cash equivalents | $ 138,679 | $ 190,698 | |
Short-term investments | 154,157 | 141,239 | [1] |
Long-term investments | 12,246 | 0 | [1] |
Total cash equivalents and investments | $ 305,082 | $ 331,937 | |
[1] | The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date. |
Investments - Contractual Matur
Investments - Contractual Maturity (Details) - USD ($) | 3 Months Ended | 9 Months Ended | |
Mar. 31, 2022 | Sep. 30, 2021 | Dec. 31, 2021 | |
Investments, Debt and Equity Securities [Abstract] | |||
Due in 1 year or less | $ 292,836,000 | $ 143,014,000 | |
Due in 1 to 2 years | 12,246,000 | 0 | |
Instruments not due at a single maturity date | 0 | 188,923,000 | |
Total cash equivalents and investments | 305,082,000 | $ 331,937,000 | |
Other-than-temporary impairments on available-for-sale securities | $ 0 | $ 0 |
Prepaid Expenses And Other Cu_3
Prepaid Expenses And Other Current Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |||
Accrued interest on short-term available-for-sale securities | $ 661 | $ 816 | |
Prepaid equipment service contracts | 446 | 360 | |
Prepaid external research and development and outside services | 3,086 | 3,074 | |
Prepaid software | 1,054 | 624 | |
Prepaid insurance | 1,691 | 2,644 | |
Prepaid rent and other | 517 | 527 | |
Prepaid expenses and other current assets | $ 7,455 | $ 8,045 | [1] |
[1] | The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date. |
Property and Equipment, Net (De
Property and Equipment, Net (Details) - USD ($) $ in Thousands | 3 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | ||
Property, Plant and Equipment [Line Items] | ||||
Total property and equipment | $ 18,327 | $ 18,139 | ||
Less: Accumulated depreciation and amortization | (3,817) | (3,259) | ||
Total property and equipment, net | 14,510 | 14,880 | [1] | |
Depreciation and amortization | 557 | $ 444 | ||
Lab equipment | ||||
Property, Plant and Equipment [Line Items] | ||||
Property, plant and equipment, gross | 8,317 | 8,164 | ||
Leasehold improvements | ||||
Property, Plant and Equipment [Line Items] | ||||
Property, plant and equipment, gross | 9,344 | 9,335 | ||
Furniture and fixtures | ||||
Property, Plant and Equipment [Line Items] | ||||
Property, plant and equipment, gross | 608 | 596 | ||
Computer equipment | ||||
Property, Plant and Equipment [Line Items] | ||||
Property, plant and equipment, gross | $ 58 | $ 44 | ||
[1] | The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date. |
Accrued Expenses And Current _3
Accrued Expenses And Current Portion Of Other Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | |
Payables and Accruals [Abstract] | |||
Accrued compensation | $ 1,258 | $ 4,570 | |
Accrued taxes | 50 | 0 | |
External research and development | 5,751 | 2,655 | |
Accrued outside services | 1,227 | 1,598 | |
Other accrued expenses | 42 | 240 | |
Total accrued expenses | $ 8,328 | $ 9,063 | [1] |
[1] | The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date. |
Accrued Expenses And Current _4
Accrued Expenses And Current Portion Of Other Liabilities - Current Other Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | |
Payables and Accruals [Abstract] | |||
Current portion of unvested early exercised share liability | $ 1,225 | $ 1,364 | |
ESPP withholdings | 304 | 92 | |
Total current portion of other liabilities | $ 1,529 | $ 1,456 | [1] |
[1] | The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date. |
Stock-Based Compensation - Narr
Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | |
Oct. 31, 2020 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Weighted-average grant-date fair value, options granted (in dollars per share) | $ 5.05 | |||
Stock options, unrecognized cost | $ 53,500 | $ 49,900 | ||
Current liabilities related to shares that were subject to repurchase | 1,225 | 1,364 | ||
Current portion of other liabilities | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Current liabilities related to shares that were subject to repurchase | 1,200 | 1,400 | ||
Other noncurrent liabilities | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Non-current liabilities related to shares that were subject to repurchase | $ 800 | $ 1,100 | ||
2020 Equity Incentive Plan | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Expiration period | 10 years | |||
Shares that may be issued, percent increase as total of common stock outstanding | 5.00% | |||
Number of shares that may have been issued (in shares) | 17,568,821 | |||
Vesting period | 4 years | |||
Number of shares reserved for future issuance (in shares) | 4,911,664 | |||
Stock options | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options recognized, weighted average period | 2 years 10 months 28 days | 2 years 11 months 4 days | ||
Expected shares to be purchased under Employee Stock Purchase Plan | The ESPP | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Number of shares that may have been issued (in shares) | 688,000 | |||
Number of shares reserved for future issuance (in shares) | 1,718,410 | |||
Number of shares that may be issued, increase percentage | 1.00% | |||
Number of shares that may be issued, increase (in shares) | 1,376,000 | |||
Employee stock purchase plan (in shares) | 0 | 0 | ||
Restricted Stock Units (RSUs) | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options recognized, weighted average period | 2 years 21 days | |||
Unrecognized stock based compensation | $ 20,800 | |||
Restricted Stock | ||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||||
Stock options recognized, weighted average period | 2 years 3 months 29 days | |||
Unrecognized stock based compensation | $ 300 |
Stock-Based Compensation - Stoc
Stock-Based Compensation - Stock Option Activity (Details) $ / shares in Units, $ in Thousands | 3 Months Ended |
Mar. 31, 2022USD ($)$ / sharesshares | |
Number of Options | |
Beginning Balance (in shares) | shares | 6,590,400 |
Granted (in shares) | shares | 1,905,502 |
Forfeited (in shares) | shares | (131,795) |
Exercised (in shares) | shares | (246,029) |
Ending Balance (in shares) | shares | 8,118,078 |
Weighted-Average Exercise Price | |
Beginning Balance (dollars per share) | $ / shares | $ 14.33 |
Granted (dollars per share) | $ / shares | 7.41 |
Forfeited (dollars per share) | $ / shares | 11.73 |
Exercised (dollars per share) | $ / shares | 2.15 |
Ending Balance (dollars per share) | $ / shares | $ 13.12 |
Stock Option Activity, Additional Disclosures [Abstract] | |
Balance, Weighted-Average Remaining Contractual Term | 8 years 9 months 3 days |
Balance, Aggregate Intrinsic Value | $ | $ 11,974 |
Stock-Based Compensation - Rest
Stock-Based Compensation - Restricted Stock Awards Activity (Details) - Restricted Stock And Restricted Stock Units $ / shares in Units, $ in Thousands | 3 Months Ended |
Mar. 31, 2022USD ($)$ / sharesshares | |
Number of Restricted Stock | |
Unvested Beginning Balance (in shares) | shares | 787,719 |
Granted - restricted stock awards and units (in shares) | shares | 836,446 |
Vested and converted to shares (in shares) | shares | (115,153) |
Forfeited (in shares) | shares | (45,244) |
Unvested Ending Balance (in shares) | shares | 1,463,768 |
Weighted-Average Grant Date Fair Value | |
Unvested Beginning Balance (in dollars per share) | $ / shares | $ 26.88 |
Granted - restricted stock awards and units (in dollars per share) | $ / shares | 7.11 |
Vested and converted to shares (in dollars per share) | $ / shares | 27.22 |
Forfeited (in dollars per share) | $ / shares | 14.57 |
Unvested Ending Balance (in dollars per share) | $ / shares | $ 16.08 |
Unvested, Weighted Average Remaining Vesting Life | 2 years 4 months 28 days |
Unvested, Aggregate Intrinsic Value | $ | $ 10,583 |
Stock-Based Compensation - Re_2
Stock-Based Compensation - Restricted Stock Awards (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | $ 7,788 | $ 5,238 |
Research and development expenses | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | 3,804 | 2,554 |
General and administrative expenses | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Stock-based compensation expense | $ 3,984 | $ 2,684 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Income Tax Disclosure [Abstract] | ||
Income tax expense | $ 0 | $ 0 |
Net Loss Per Share (Details)
Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 58 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |||
Net loss | $ (36,263) | $ (26,086) | $ (299,200) |
Weighted-average shares of common stock, basic (in shares) | 55,839,336 | 54,152,656 | |
Weighted-average shares of common stock, diluted (in shares) | 55,839,336 | 54,152,656 | |
Net loss per share, basic (in dollars per share) | $ (0.65) | $ (0.48) | |
Net loss per share, diluted (in dollars per share) | $ (0.65) | $ (0.48) |
Net Loss Per Share - Antidiluti
Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount (in shares) | 9,962,346 | 8,010,023 |
Stock options to purchase common stock | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount (in shares) | 7,539,416 | 5,307,444 |
Early exercised stock options subject to future vesting | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount (in shares) | 578,662 | 1,443,842 |
Restricted stock awards subject to future vesting | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount (in shares) | 80,016 | 217,877 |
Restricted stock units subject to future vesting | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount (in shares) | 1,383,752 | 904,847 |
Expected shares to be purchased under Employee Stock Purchase Plan | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share, amount (in shares) | 380,500 | 136,013 |
Commitment and Contingencies -
Commitment and Contingencies - Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | |
Dec. 31, 2021 | Oct. 31, 2021 | |
Research And Development Services | Tempus Labs, Inc. | ||
Schedule Of Asset Acquisition [Line Items] | ||
Services contract term | 3 years | |
Annual minimum commitment payment in year one | $ 1.5 | |
Annual minimum commitment payment in year two | 2 | |
Annual minimum commitment payment in year three | 2.5 | |
Sales milestone payment | $ 22.4 | |
Sales milestone payment in shares of common stock, percent threshold | 50.00% | |
Asset Purchase Agreement | ||
Schedule Of Asset Acquisition [Line Items] | ||
Sales milestone payment | $ 29 |
Leases - Additional Information
Leases - Additional Information (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | ||||
Feb. 28, 2021USD ($)ft² | Mar. 31, 2020USD ($)ft² | Mar. 31, 2022USD ($) | Mar. 31, 2021USD ($) | Dec. 31, 2021USD ($) | ||
Lessee, Lease, Description [Line Items] | ||||||
Operating lease right-of-use assets | $ 26,370 | $ 26,904 | [1] | |||
Lease liabilities | 33,465 | 33,762 | ||||
Lease payments | 1,000 | $ 1,200 | ||||
301 Binney Street, Cambridge, Massachusetts | ||||||
Lessee, Lease, Description [Line Items] | ||||||
Lease term | 11 years | |||||
Facility size | ft² | 40,514 | |||||
Initial annual base rent | $ 4,100 | |||||
Escalating rent payments, percent | 3.00% | |||||
Letter of credit | $ 2,000 | |||||
Tenant improvement allowances | $ 3,700 | |||||
Improvement costs incurred, reimbursed by lessor | 3,700 | |||||
Operating lease right-of-use assets | 23,200 | 23,600 | ||||
Lease liabilities | $ 29,300 | 29,700 | ||||
Incremental borrowing rate | 8.50% | |||||
Remaining lease term | 8 years 11 months | |||||
San Mateo, California. Original Lease | ||||||
Lessee, Lease, Description [Line Items] | ||||||
Facility size | ft² | 8,075 | |||||
San Mateo, California. February 2021 Lease Agreement | ||||||
Lessee, Lease, Description [Line Items] | ||||||
Facility size | ft² | 17,340 | |||||
Initial annual base rent | $ 1,200 | |||||
Escalating rent payments, percent | 3.00% | |||||
Operating lease right-of-use assets | $ 3,200 | 3,300 | ||||
Lease liabilities | $ 4,200 | $ 4,100 | ||||
Incremental borrowing rate | 11.18% | |||||
Security deposit | $ 59 | |||||
Remaining lease term | 4 years 3 months | |||||
[1] | The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date. |
Leases - Supplemental Balance S
Leases - Supplemental Balance Sheet Information - Operating Leases (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 | |
Assets: | |||
Operating lease assets | $ 26,370 | $ 26,904 | [1] |
Liabilities: | |||
Current portion of operating lease liabilities | 2,502 | 2,109 | [1] |
Noncurrent operating lease liabilities | 30,963 | 31,653 | [1] |
Total operating lease liabilities | $ 33,465 | $ 33,762 | |
[1] | The balance sheet as of December 31, 2021 is derived from the audited financial statements as of that date. |
Leases - Summary of Lease Costs
Leases - Summary of Lease Costs (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Lessee, Lease, Description [Line Items] | ||
Operating lease cost | $ 1,278 | $ 1,384 |
Research and development | ||
Lessee, Lease, Description [Line Items] | ||
Operating lease cost | 767 | 1,008 |
General and administrative | ||
Lessee, Lease, Description [Line Items] | ||
Operating lease cost | $ 511 | $ 376 |
Leases - Schedule of Maturities
Leases - Schedule of Maturities on Lease Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
Leases [Abstract] | ||
Remaining nine months of 2022 | $ 3,977 | |
2023 | 5,581 | |
2024 | 5,749 | |
2025 | 5,921 | |
2026 and thereafter | 26,707 | |
Total undiscounted lease payments | 47,935 | |
Less: Present value adjustment | (14,470) | |
Present value of operating lease liabilities | $ 33,465 | $ 33,762 |
Related Party Disclosures (Deta
Related Party Disclosures (Details) - Affiliated Entity - USD ($) | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Two River Consulting, LLC | ||
Related Party Transaction [Line Items] | ||
Expenses from transaction with related party | $ 23,000 | $ 200,000 |
Bellco Capital, LLC | ||
Related Party Transaction [Line Items] | ||
Expenses from transaction with related party | $ 6,300 | $ 6,300 |